

# Iron supplementation in patients with anemia

<b>Submission date</b> 20/06/2022	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 25/10/2022	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 20/04/2023	<b>Condition category</b> Haematological Disorders	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Anemia is a condition in which there are not enough healthy red blood cells to carry adequate oxygen to the body's tissues. It is treated with iron supplementation. Up to now, the blanket distribution of iron supplementation in Indonesia to reproductive-age women has continued with unsatisfactory results. The aim of the study is to evaluate the effectiveness of iron supplementation to increase hemoglobin levels.

### Who can participate?

Patients aged between 15–49 years with moderate or severe anemia

### What does the study involve?

Participants are randomly allocated to take iron tablets with folic acid or iron tablets with multivitamins for 30 days. Hemoglobin levels are measured at the start of the study and after 30 days

### What are the possible benefits and risks of participating?

Participants may benefit from a free medical check related to their anemia and treatment with iron supplementation. There is a risk of side effects from iron supplementation such as a gastrointestinal ulcer with different symptoms (nausea, vomiting)

### Where is the study run from?

1. Universitas Padjadjaran (Indonesia)
2. Ministry of Health in Teluk Bintuni, West Papua Province (Indonesia)

### When is the study starting and how long is it expected to run for?

September 2018 to November 2019

### Who is funding the study?

1. Universitas Padjadjaran (Indonesia)
2. Teluk Bintuni Hospital (Indonesia)
3. Ministry for Research, Technology, and Higher Education (Indonesia)

### Who is the main contact?

Rano K. Sinuraya, MPH, [r.k.sinuraya@unpad.ac.id](mailto:r.k.sinuraya@unpad.ac.id)

# Contact information

**Type(s)**

Scientific

**Contact name**

Dr Yasinta Rakanita

**ORCID ID**

<http://orcid.org/0000-0002-3156-2407>

**Contact details**

Pharmacy Faculty of Padjadjaran University  
Jatinangor-Sumedang,  
Jatinangor-Sumedang  
Indonesia  
45363  
+62 (0)8114533884  
[yasinta18001@mail.unpad.ac.id](mailto:yasinta18001@mail.unpad.ac.id)

# Additional identifiers

**EudraCT/CTIS number**

Nil known

**IRAS number****ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

0719010092

# Study information

**Scientific Title**

Adherence to iron supplementation in reproductive-age women with anemia in West Papua, Province, Indonesia

**Study objectives**

Sociodemographic, adherence to iron supplementation, knowledge of anemia affected to anemia recovery level.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 15/02/2019, Padjadjaran University Research Ethics Committee (Jl. Prof. Eyckman Number 38, Bandung, 40161, Indonesia; +62 (0)22 2038697, kepk.fk.unpad@gmail.com), ref: 172 /UN6.KEP/EC/2019

**Study design**

Quasi-experimental study

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Community

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details to request a participant information sheet

**Health condition(s) or problem(s) studied**

Moderate and severe anemia

**Interventions**

Participants are randomised to take one of two oral supplements daily for 30 days. The iron fumarate-folic acid (IF-FA) supplement contains the elemental iron equivalent of 30 mg and 400 µg of folic acid. The iron gluconate-multivitamins (IG-MV) supplement contains the elemental iron equivalent of 0.9 mg, 500 µg of folic acid, and multivitamins, such as 15 mg vitamin B1 HCl, 0.25 mg vitamin B2, 0.25 mg vitamin B6 HCl, 12.5 mg vitamin C, 1.5 mg calcium pantothenate, 10 mg nicotinamide, 0.5 mg folic acid, 0.65 mg cupric sulfate, and 100 mg dried beef liver. Data is collected on the factors that influence medication adherence is obtained from the calculation of the remaining tablets given for 30 days; the Medication Adherence Rating Score (MARS) tool; and the participants' perspective on adherence. For biomarker observations, hemoglobin levels are measured pre and post intervention.

**Intervention Type**

Supplement

**Primary outcome measure**

Hemoglobin level measured using the portable analyzer HemoCue 201 at baseline and 30 days

**Secondary outcome measures**

Correlation factors to the success of anemia therapy such as ethnicity, adherence to MARS and pill counting methods, and the type of supplementation, measured at baseline and 30 days

**Overall study start date**

01/09/2018

**Completion date**

29/11/2019

## **Eligibility**

**Key inclusion criteria**

1. Moderate and severe anemia
2. Aged between 15–49 years
3. Consented to take part in the study

**Participant type(s)**

Patient

**Age group**

Mixed

**Sex**

Female

**Target number of participants**

222

**Total final enrolment**

110

**Key exclusion criteria**

1. Did not complete the informed consent
2. Incomplete data collected pre and post session
3. Unable to communicate

**Date of first enrolment**

01/10/2019

**Date of final enrolment**

30/10/2019

## **Locations**

**Countries of recruitment**

Indonesia

**Study participating centre**

**Pusat Studi Genetik Medis, Fakultas Kedokteran Universitas Padjadjaran**

Jl. Prof. Eyckman N0. 38

Bandung

Indonesia

40161

# Sponsor information

## Organisation

Padjadjaran University

## Sponsor details

Department of Pharmacology and Clinical Pharmacy

Faculty of Pharmacy

Jl.Raya Bandung Sumedang KM. 21, Jatinangor

Sumedang

Indonesia

45363

+62 (0)84288828

r.k.sinuraya@unpad.ac.id

## Sponsor type

University/education

## Website

<https://www.unpad.ac.id>

## ROR

<https://ror.org/00xqf8t64>

## Organisation

Teluk Bintuni General Hospital

## Sponsor details

Jl. Raya Sibena KM 7, Teluk Bintuni

Teluk Bintuni, West Papua

Indonesia

98141

+62 (0)21 294 50 999

eka.suradji@ukrida.ac.id

## Sponsor type

Hospital/treatment centre

## Organisation

Indonesian Ministry for Research, Technology, and Higher Education

## Sponsor details

Gedung D Jl. Jenderal Sudirman Pintu Satu, Senayan, Jakarta Pusat  
DKI Jakarta  
Indonesia  
10270  
+62 (0)8114533884  
pintu@ristekdikti.go.id

**Sponsor type**

Government

**Website**

<https://kemendikbud.go.id>

## **Funder(s)**

**Funder type**

University/education

**Funder Name**

Universitas Padjadjaran

**Alternative Name(s)**

Padjadjaran University, UNPAD

**Funding Body Type**

Government organisation

**Funding Body Subtype**

Universities (academic only)

**Location**

Indonesia

**Funder Name**

Teluk Bintuni Hospital

**Funder Name**

Kementerian Riset Teknologi Dan Pendidikan Tinggi Republik Indonesia

**Alternative Name(s)**

Ministry of Research, Technology and Higher Education, Kementerian Ristek Dikti, Kementerian Riset dan Teknologi

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

Indonesia

## Results and Publications

**Publication and dissemination plan**

Publication in the International Journal of Women's Health and Reproduction Sciences

**Intention to publish date**

17/08/2022

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study will be stored in a non-publicly available repository <https://repository.unpad.ac.id/> (still in maintenance).

**IPD sharing plan summary**

Stored in non-publicly available repository

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/01/2023	20/04/2023	Yes	No